Covid-19 roundup: Eli Lil­ly de­clares suc­cess on JAK block­er in NIH tri­al; UK gives small biotech a big vac­cine deal

The NIH-led study that gave the world the first pos­i­tive, ran­dom­ized remde­sivir re­sult has come back with a sec­ond one, show­ing that, when com­bined with remde­sivir, an Eli Lil­ly mol­e­cule can slight­ly im­prove on time to re­cov­ery over remde­sivir alone.

The ACTT-2 tri­al, a fol­low-up that be­gan af­ter the remde­sivir sec­tion was com­plet­ed, en­rolled over 1,000 hos­pi­tal­ized Covid-19 pa­tients and found that those giv­en the an­tivi­ral remde­sivir plus the Eli Lil­ly JAK in­hibitor baric­i­tinib re­cov­ered a me­di­an of “ap­prox­i­mate­ly one day” soon­er than those giv­en remde­sivir alone. Sim­i­lar to the IL-6 in­hibitors from Re­gen­eron and Roche — which failed in Phase III tri­als — baric­i­tinib was de­signed to tamp down the over­ac­tive im­mune re­sponse seen in the lat­er stages of Covid-19.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER